The ,3-adrenergic and calcium channel blocking agents are known to reduce heart rate and alter myocardial contractility. More recent evidence suggests that both agents affect the metabolic consequences of ischemia, independent of their effects on heart rate and contractility. We used a low-flow model of ischemia in swine with heart rate held constant by atrial pacing. Blood was shunted from the carotid artery to the left anterior descending coronary artery through a controlled-flow roller pump to assess the threshold flow for the rise in extracellular potassium ([K4Ie) and fall in extracellular pH (pHe) associated with ischemia during control situations and after the administration of either propranolol or verapamil. We also measured the changes in activation delay and contractility associated with graded flow reductions in the presence and absence of these drugs. We found that when heart rate is held constant, 1) verapamil shifts the threshold flow for [K4Ie and pH, to lower levels, but propranolol does not; 2) verapamil lessens activation delay, while propranolol aggravates the delay; and 3) verapamil reduces afterload and selectively depresses contractility in the reperfused ischemic zone. We conclude that the calcium channel blockers and the f-adrenergic-blocking agents have different effects and possibly different modes of action and should not be considered interchangeable when evaluating therapeutic options for patients with ischemic heart disease. (Circulation 1989;79: 939-947) T he ,3-adrenergic-blocking agents and the calcium channel blocking agents are both used in the treatment of patients with effortinduced ischemial2 due to coronary artery disease. The beneficial effects of these agents are attributed to their ability to reduce heart rate and contractility, thereby lessening the myocardial oxygen requirement. In addition, there is evidence to suggest that both the 8-adrenergic-and the calcium channel blocking agents may alter the metabolic consequences of reduced coronary blood flow independently of changes in heart rate or contractility.3,4 after the complete interruption of coronary blood flow5-8 been attributed to this mechanism. These effects would be expected to allow the myocardium to tolerate lower levels of coronary blood flow without becoming ischemic.
The ,3-adrenergic and calcium channel blocking agents are known to reduce heart rate and alter myocardial contractility. More recent evidence suggests that both agents affect the metabolic consequences of ischemia, independent of their effects on heart rate and contractility. We used a low-flow model of ischemia in swine with heart rate held constant by atrial pacing. Blood was shunted from the carotid artery to the left anterior descending coronary artery through a controlled-flow roller pump to assess the threshold flow for the rise in extracellular potassium ([K4Ie) and fall in extracellular pH (pHe) associated with ischemia during control situations and after the administration of either propranolol or verapamil. We also measured the changes in activation delay and contractility associated with graded flow reductions in the presence and absence of these drugs. We found that when heart rate is held constant, 1) verapamil shifts the threshold flow for [K4Ie and pH, to lower levels, but propranolol does not; 2) verapamil lessens activation delay, while propranolol aggravates the delay; and 3) verapamil reduces afterload and selectively depresses contractility in the reperfused ischemic zone. We conclude that the calcium channel blockers and the f-adrenergic-blocking agents have different effects and possibly different modes of action and should not be considered interchangeable when evaluating therapeutic options for patients with ischemic heart disease. (Circulation 1989; 79: 939-947)
T he ,3-adrenergic-blocking agents and the calcium channel blocking agents are both used in the treatment of patients with effortinduced ischemial2 due to coronary artery disease. The beneficial effects of these agents are attributed to their ability to reduce heart rate and contractility, thereby lessening the myocardial oxygen requirement. In addition, there is evidence to suggest that both the 8-adrenergic-and the calcium channel blocking agents may alter the metabolic consequences of reduced coronary blood flow independently of changes in heart rate or contractility. 3, 4 The ability of both groups of agents to decrease the rate of accumulation of extracellular K' and H' after the complete interruption of coronary blood flow5-8 been attributed to this mechanism. These effects would be expected to allow the myocardium to tolerate lower levels of coronary blood flow without becoming ischemic.
Our Atter a midsternal thoracotomy, the heart was suspended in the pericardium, and the right atrium was paced to maintain a constant heart rate, which ranged from 110 to 160 beats/min. A carotid artery to lett anterior descending (LAD) coronary artery shunt was produced as previously described.9 In brief, a polyethylene catheter was placed in the right carotid artery; 7,000 units heparin were administeted intravenously; the catheter was routed through a roller pump (Cole-Palmer); and the distal end was inserted into the LAD below the first diagonal branch (Figure 1 ). The control LAD flow was set at 1.2-1.5 ml/kg body wt/min and ranged froni 30 to 50 ml/min. Heparin (3, previously described. 13 In addition, the signals from two randomly selected K' electrodes and two randomly selected pH electrodes were continuously recorded along with the hemodynamic data on a Graphtec Linearcorder. The in vivo integrity of the electrodes was determined before and after each LAD flow reduction sequence by the rapid intravenous injection of 3 meq KCI and by 60-second periods of respiratory acidosis. Data were accepted only from electrodes that demonstrated reproducible responses to each KCI bolus or period of acidosis and that maintained a stable baseline throughout the study. In all, 66 of 101 K' electrodes (65%) and 40 of 75 pH electrodes (53%) met these calibration criteria.
Local bipolar electrograms were recorded by five Teflon-coated stainless-steel bipolar electrode pairs placed in the subepicardium. One electrode pair was placed in the nonischemic zone, and four pairs were placed in the ischemic zone within 5 mm of the Kt-sensitive electrodes. The bipolar electrograms were filtered between 50 and 500 Hz and continuously monitored along with a lead II electrocardiogram. This filtering permitted identification of the high-frequency deflection of the electrogram until it became fractionated. The signals were recorded 15 seconds before each flow reduction step on a Honeywell 1858 visicorder at a paper speed of 400 mm/ sec. Local activation time was measured from the onset of the QRS complex in the electrocardiogram to the peak of the intrinsic, high-frequency deflection in each local electrogram. In some experi- 1,792+75
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*p<O.O1; tp<0.001.
ments, ultrasonic crystals were inserted into the ischemic and nonischemic regions to determine segment length shortening as previously described.9
The preparation was allowed to stabilize for at least 60 minutes after placement of the ion-sensitive electrodes. Blood flow into the LAD was reduced sequentially at 5-minute intervals as follows: 50, 40, 30, 20, 15, 10, 5, 2.5, and 0 ml/min; blood flow then returned to control flow. The first sequential flow reduction served as a control (C1). The animals were then divided into three groups: control (CQ, n = 8), verapamil (V, n = 10), and propranolol (P, n = 9).
In the verapamil group, an intravenous loading dose of 0.2 mg/kg verapamil was initiated 20 minutes after C1 and administered over a 20-minute period. This was followed by a constant infusion of 6.5 ,ug/ kg/min. In the propranolol group, an intravenous loading dose of 0.4 mg/kg propranolol was initiated 40 minutes after C1 and administered over a 5-minute period. This was followed by a constant infusion of 3 ,g/kg/min. In all groups, the second flow reduction was performed 50 minutes after C1. These drug concentrations were similar to those previously used by us and others6-8 to achieve serum levels comparable to those achieved in humans.
[K]e,, pHe, and local activation changes were monitored to determine the flow at which the measured parameter first changed during the graded LAD flow reduction. This was labeled the threshold flow for that parameter and was identified as follows: Table 1 shows the mean values of serum potassium, arterial pH, heart rate, mean arterial pressure, and maximum left ventricular dP/dt in each group before the first and second flow reductions. These variables were similar in the three groups before the first flow reduction and returned to their control values after reperfusion. The values of serum potassium, arterial pH, and heart rate before the second flow reduction were the same as those before the first in all groups. Mean arterial pressure and maximum dP/dt were also unchanged before the second flow reduction in the control group. In contrast, verapamil caused a decrease in mean arterial pressure of 31 mm Hg and a decrease in maximum dP/dt of 32% (p <0.001). Propranolol decreased maximum dP/dt by 23% (p < 0.01) but did not change mean arterial pressure significantly. Figure 5 shows the activation delay associated with the progressive reduction of coronary flow in each group. In the control group, activation delay first occurred at a flow of 14.8 ± 1.7 ml/min and was equivalent in the Cl and C2 reductions. The flow associated with the onset of the activation delay in the preverapamil and prepropranolol flow reductions were comparable to the control group. After verapamil, activation delay first occurred at 9.2 ± 1.3 ml/min and was less at lower levels of flow than in the preverapamil sequence. These differences were statistically significant (p <0.005). Propranolol did not alter the flow at which activation delay first occurred but increased the magnitude of the activation delay at coronary flows less than 10 ml/min. FIGURE 5 . Bar charts of effects of verapamil (V1 and propranolol (P) on activation delay during successive gradedflow reductions. Note that verapamil significantly lessens these delays at flows between 5.0 and 0 ml/min while propranolol aggravates them at 5. 0 and 2.5 ml/min. C1, first control reduction; C2, second control reduction; V, verapamil reduction; P, propranolol reduction.
of ischemia to lower levels and lessens the activation delay associated with low-flow ischemia. In contrast, propranolol shows neither of these effects.
Further, verapamil, not propranolol, decreases afterload and selectively depresses contractility within the ischemic area. Previous work has shown that the calcium channel blocking agents verapamil and diltiazem attenuate the rise in extracellular K' and fall in extracellular pH that occurs in the setting of no-flow ischemia.7,814 Our results show that verapamil also reduces the coronary flow at which the first changes in [K+]e and pHe occur. The possible mechanisms by which verapamil induces this effect include improving nutrient flow to the ischemic zone; reducing myocardial work by decreasing afterload, contractility and rate; or providing metabolic protection independent of changes in myocardial work. In our pig model with controlled coronary blood flow and low collateral circulation,'5 an effect of verapamil on nutrient flow is unlikely. Indeed, others have shown that verapamil does not alter regional myocardial blood flow in association with low-flow ischemia even in dogs where collateral flow is more abundant.1617 In each of our experiments, heart rate was constant, thus eliminating this parameter. However, mean arterial blood pressure was significantly reduced after verapamil. In addition, verapamil significantly depressed contractility in the nonischemic zone, had an even greater effect in the reperfused myocardium, and caused a further decrease in contractility as coronary flow was progressively reduced. This selective depression of contractility in the ischemic area is similar to that reported by Smith et al18 and by Urquhart et al. 16 Romson et al'9 used a flow reduction protocol and doses of verapamil similar to those of our study, but reported a nonselective depression of contractility in the ischemic and nonischemic myocardium. Sherman et al17 reported that in the setting of no-flow ischemia, verapamil enhanced postextrasystolic potentiation in the center of the ischemic zone. The apparent differences between their results and our observations are probably due to differences in experimental design.
In our present experiments, as in our previous studies of low-flow ischemia,9 the decreases in fractional shortening during the predrug flow reduction never occurred at LAD flows that did not cause a change in There is convincing evidence to support the concept that verapamil provides metabolic protection to the ischemic myocardium even in the absence of a primary effect on contractility. Lange et a13 observed that verapamil lessened the decrease in ATP associated with 15 minutes of total coronary occlusion. Watson et a120 administered verapamil after an 80% reduction in coronary flow had caused extracellular pH to fall to the range of 6.1-6.8 and observed a return of pH towards control values. Although they did not record contractility, it is reasonable to assume that it had decreased in association with the fall in pHe.
The changes that we have observed after the administration of verapamil do not necessarily imply that verapamil delayed the occurrence of ischemic cell injury in our preparation. However, Reimer et a121 reported that in dogs the administration of verapamil before a 40-minute occlusion of the circumflex coronary artery was associated with significantly less necrosis than was present in the untreated animals.
Verapamil is known to decrease the frequency of ventricular arrhythmias, to prevent ventricular fibrillation,22-25 and to lessen the degree of conduction slowing during no-flow ischemia. 8 exaggerates the conduction delay at each level of low-flow ischemia. This result, when combined with the 23% fall in dP/dt, indicates that /3-blocking doses of propranolol were used. It is consistent with other studies showing that propranolol administration12 and sympathetic denervation32 aggravate local activation delay induced by no-flow ischemia when heart rate is fixed, whereas isoproterenol administration6 and sympathetic stimulation33 lessen the activation delay.
In summary, our results indicate that when heart rate is held constant, verapamil provides metabolic protection to the myocardium that permits coronary flow to be reduced to lower levels before the ionic markers of ischemia appear. In addition, verapamil lessens the activation slowing associated with ischemia. Propranolol does not permit a greater reduction in coronary flow before the appearance of the ionic markers of ischemia and aggravates the activation slowing associated with ischemia. Verapamil decreases afterload, selectively depresses contraction within the reperfused ischemic zone, and may dissociate the contractile, ionic, and electrical changes that occur as coronary flow is reduced. In contrast, propranolol does not reduce afterload and is reported to improve contractility within the ischemic zone. 34, 35 Although further studies are needed to determine if the effects of verapamil on ionic and electrical markers of low-flow ischemia are secondary to its effects on contractility and afterload, our results suggest that the calcium channel blocking agents and the ,B-adrenergic-blocking agents should not be considered to be equivalent or interchangeable when evaluating therapeutic options for patients with ischemic heart disease.
